Local recurrence and metastasis in patients with malignant melanomas after surgery: A single-center analysis of 202 patients in South Korea

Soo Ick Cho¹, Jaewon Lee¹, Gwanghyun Jo¹, Sang Wha Kim², Kyung Won Minn², Ki Yong Hong³, Seong Jin Jo¹, Kwang Hyun Cho¹, Byung Jun Kim²*, Je-Ho Mun¹*

¹ Department of Dermatology, Seoul National University College of Medicine, Seoul, South Korea, ² Department of Plastic and Reconstructive Surgery, Seoul National University College of Medicine, Seoul, South Korea, ³ Department of Plastic and Reconstructive Surgery, Dongguk University Ilsan Hospital, Goyang, South Korea

These authors contributed equally to this work.

* jehomun@snu.ac.kr (JHM); bjkim79@gmail.com (BJK)

Abstract

Malignant melanoma (MM) is a lethal skin cancer in Western countries. Although the incidence is low in Asians compared to that in Caucasians, it is increasing. However, literature regarding risk factors for prognosis of MM patients who have undergone surgical excision in Asia is limited. This study aimed to investigate the predictive factors for local recurrence and metastasis in MM patients who underwent surgical treatment at a single tertiary-level hospital in Korea. Patients who underwent surgery for MM at our institution between January 1998 and December 2014 were analyzed. We retrospectively investigated risk factors for local recurrence and metastasis after surgery. In cases with distant metastasis, tumor thickness (adjusted Hazard Ratio (HR), 6.139; 95% confidence interval (CI), 2.152 to 17.509; \( P = 0.001 \)) and increased mitotic number \((0-1/mm^2 \text{ vs } 2-6/mm^2): \text{adjusted HR, 4.483; 95\% CI, 1.233 to 16.303; } P = 0.023\); \((0-1/mm^2 \text{ vs } > 6/mm^2): \text{adjusted HR, 10.316; 95\% CI, 2.871 to 37.063; } P < 0.001\)) were associated with risk in multivariate analysis.

Regarding local recurrence, tumor thickness \((T4 \geq 4mm \text{ vs } T1)\) was found to be a significant risk factor \((P = 0.001)\). Our data revealed tumor thickness and increased mitotic count were significant risk factors for local recurrence and distant metastasis in Korean patients with MM after surgery.

Introduction

Malignant melanoma (MM) is a fatal skin tumor originating from melanocytes. Although its reported age-standardized incidence is only 0.4–0.6 per 100,000 people in Korea, it is one of the leading causes of death among skin cancers. Biological and environmental factors such as the number of common or atypical nevi, intermittent and intense sun exposure, and some phenotypic characteristics (light, fair color of skin, hair and eyes; family history of MM)
increase the risk of MM.[2–4] Various epidemiologic and clinical features of MM have been studied to date.[5–7]

The incidence of MM is lower in eastern countries than in western countries.[8] Recently, however, the incidence and prevalence of MM has been increasing annually.[1] MM in Asian patients affects different sites and exhibits different clinical features and worse prognosis than those in western patients.[9–11]

To our knowledge, there have been few studies regarding the risk factors for local recurrence and metastasis in MM in Korea.[12–14] The aim of this study was to report the surgical experience of patients with MM at a tertiary hospital in South Korea over the past 17 years. We investigated key predictive factors associated with local recurrence and metastasis after surgery.

Materials and methods

Study design

We conducted a retrospective analysis of subjects who underwent curative surgery for MM at the Seoul National University Hospital between January 1998 and December 2014. Demographic, clinical, and follow-up data of subjects were obtained from electronic medical records. Histopathological information was obtained from pathology reports from the Department of Pathology.

The following information was obtained for each subject: (1) demographic data (sex, age); (2) history of local recurrence or metastasis; and (3) clinical and histopathological features (tumor site, ulceration, resection margin, tumor thickness, information about lymph nodes, mitotic counts, and histologic subtype). Local recurrence and metastasis were identified at outpatient clinic visits.

Statistical analysis

IBM SPSS statistics version 23.0 (IBM corp., Armonk, NY, USA) was used for statistical analysis. The differences in local recurrence or metastasis associated with demographic factors (sex and age), clinical and histopathological data (tumor site, ulceration, resection margin, tumor thickness, information about lymph nodes, mitotic counts, and histologic subtype) were considered statistically significant if the P-value was < 0.05. Univariate and multivariate Cox regression models for local recurrence and metastasis were analyzed with the forward likelihood ratio method (P-value < 0.05 was to be included in the analysis).

Ethics statement

The study protocol was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 1407-080-594). Informed consent was waived as the subjects were de-identified.

Results

Demographic and clinical characteristics of the study population

A total of 202 patients were enrolled in this study, including 85 (42.08%) men and 117 (57.92%) women. The mean age at diagnosis was 58.05 ± 12.60 years (mean ± standard deviation [S.D.], range 23–83 years). The acral site was the most common tumor site (134, 66.34%), followed by the upper and lower extremities (26, 12.87%), trunk (22, 10.89%), and head and neck (20, 9.90%). The most common histologic subtype of MM was acral lentiginous melanoma (115, 56.93%), followed by nodular (42, 20.79%), superficial spreading (29, 14.36%), lentigo maligna (14, 6.93%), and desmoplastic (2, 0.99%) lesions. Most of the surgical resection margin was free
from tumor (187, 96.39%). Lymph node (LN) exploration was performed in 79 patients (39.11%). Among all the patients who underwent LN exploration, 19 patients were positive (24.05%). All demographic and clinical variables of patients are summarized in Table 1.

**Local recurrence and association with clinicopathological factors**

During a mean follow-up period (recurrence or metastasis) of 40.54 ± 35.16 months (mean ± S.D., range 1–201 months), 19 patients (9.41%) developed local recurrence after surgery. In univariate analysis, tumors with a positive resection margin, increased tumor

| Table 1. Demographic and clinical factors of subjects. |
|------------------------------------------------------|
| Number of patients (%) |
| Sex |
| Male | 85 (42.08%) |
| Female | 117 (57.92%) |
| Age at diagnosis |
| < 64 | 138 (68.32%) |
| ≥ 65 | 64 (31.68%) |
| Body site |
| Acral | 134 (66.34%) |
| Head/neck | 20 (9.90%) |
| Upper/lower extremity | 26 (12.87%) |
| Trunk | 22 (10.89%) |
| Ulceration |
| No | 122 (60.40%) |
| Yes | 80 (39.60%) |
| Resection margin positive |
| No | 187 (96.39%) |
| Yes | 7 (3.61%) |
| not assessed | 8 |
| Breslow thickness |
| T1 | 93 (46.04%) |
| T2 | 33 (16.34%) |
| T3 | 29 (14.35%) |
| T4 | 47 (23.27%) |
| Lymph node exploration |
| Not done | 123 (60.89%) |
| Done, negative | 60 (29.70%) |
| Done, positive | 19 (9.41%) |
| Mitosis |
| 0-1/mm² | 52 (37.14%) |
| 2-6/mm² | 47 (33.57%) |
| > 6/mm² | 41 (29.29%) |
| not assessed | 62 |
| Histologic subtype |
| Acral lentiginous | 115 (56.93%) |
| Superficial spreading | 29 (14.36%) |
| Lentigo maligna | 14 (6.93%) |
| Nodular | 42 (20.79%) |
| Desmoplastic | 2 (0.99%) |
thickness (T4 [≥ 4mm] vs T1), positive LN after LN exploration, tumor with increased mitotic number, and histologic subtypes (nodular vs acral lentiginous) were significantly associated with higher rate of local recurrence. In a multivariate model, tumor thickness (T4 vs T1) (adjusted Hazard Ratio (HR), 8.461; 95% confidence interval (CI), 2.514 to 28.474; \( P = 0.001 \)) was associated with an increased risk of local recurrence (Table 2).

Distant metastasis and association of clinicopathological factors

During the follow-up period, 46 patients (22.77%) developed distant metastasis after surgery. Univariate analysis showed that body site (trunk), ulceration, increased tumor thickness
(T3/T4 vs T1), positive LN, increased mitotic number, and histologic subtypes (nodular) were significantly associated with a higher rate of metastasis. Results of a multivariate model analysis showed that tumor thickness (T4 vs T1) (adjusted HR, 6.139; 95% CI, 2.152 to 17.509; \( P = 0.001 \)) and increased mitotic number ([0-1/mm\(^2\) vs 2-6/mm\(^2\): adjusted HR, 4.483; 95% CI, 1.233 to 16.303; \( P = 0.023 \)); (0-1/mm\(^2\) vs > 6/mm\(^2\): adjusted HR, 10.316; 95% CI, 2.871 to 37.063; \( P < 0.001 \)]) were associated with an increased risk of distant metastasis (Table 3).

### Table 3. An association of clinical and histopathologic variables and distant metastasis of malignant melanoma.

| Variable                          | Univariate model       | Multivariate model (Best Model)       |
|----------------------------------|------------------------|---------------------------------------|
|                                  | Hazard ratio (95% CI)  | \( P \)-value                          | Hazard ratio (95% CI)  | \( P \)-value                          |
| Sex                              |                        |                                       |                       |
| Male                             | Reference              |                                       |                       |
| Female                           | 0.793 (0.442–1.426)    | 0.439                                 |                       |
| Age at diagnosis                 |                        |                                       |                       |
| < 64                             | Reference              |                                       |                       |
| \( \geq 65 \)                    | 0.904 (0.467–1.746)    | 0.763                                 |                       |
| Body site                        |                        |                                       |                       |
| Acral                            | Reference              |                                       |                       |
| Head/neck                        | 0.509 (0.145–2.601)    | 0.509                                 |                       |
| Upper/lower extremity            | 1.708 (0.769–3.794)    | 0.188                                 |                       |
| Trunk                            | 3.042 (1.494–6.193)    | 0.002                                 |                       |
| Ulceration                       |                        |                                       |                       |
| No                               | Reference              |                                       |                       |
| Yes                              | 1.786 (1.000–3.190)    | 0.050                                 |                       |
| Resection margin positive        |                        |                                       |                       |
| No                               | Reference              |                                       |                       |
| Yes                              | 0.762 (0.105–5.549)    | 0.788                                 |                       |
| Breslow thickness                |                        |                                       |                       |
| T1                               | Reference              |                                       | Reference             |
| T2                               | 1.575 (0.515–4.816)    | 0.426                                 | 0.971 (0.255–3.704)    | 0.966                                 |
| T3                               | 7.571 (3.160–18.138)   | \(< 0.001\)                          | 2.254 (0.698–7.274)    | 0.174                                 |
| T4                               | 10.337 (4.493–23.785)  | \(< 0.001\)                          | 6.139 (2.152–17.509)   | 0.001                                 |
| Lymph node exploration           |                        |                                       |                       |
| Not done                         | Reference              |                                       |                       |
| Done, negative                   | 0.803 (0.364–1.774)    | 0.588                                 |                       |
| Done, positive                   | 4.897 (2.144–11.185)   | \(< 0.001\)                          |                       |
| Mitosis                          |                        |                                       |                       |
| 0-1/mm\(^2\)                    | Reference              |                                       | Reference             |
| 2-6/mm\(^2\)                    | 6.126 (1.742–21.537)   | 0.005                                 | 4.483 (1.233–16.303)   | 0.023                                 |
| > 6/mm\(^2\)                    | 13.438 (3.927–45.987)  | \(< 0.001\)                          | 10.316 (2.871–37.063)  | \(< 0.001\)                          |
| Histologic subtype               |                        |                                       |                       |
| Acral lentiginous                 | Reference              |                                       |                       |
| Superficial spreading            | 1.226 (0.488–3.077)    | 0.665                                 |                       |
| Lentigo maligna                  | 0.470 (0.063–3.520)    | 0.462                                 |                       |
| Nodular                          | 6.197 (3.255–11.797)   | \(< 0.001\)                          |                       |
| Desmoplastic                     | 0.000 (0.000)          | 0.986                                 |                       |

https://doi.org/10.1371/journal.pone.0213475.t003
Discussion

There have been reports comparing surgical outcomes and prognostic factors in MM to date. [15, 16] Thomas et al. [17] reported an association between demographic and clinical factors with locoregional recurrence and death in 900 MM patients after surgery. According to the study, male sex, tumors with greater thickness, and tumors with ulceration were associated with increased local recurrence and death. Generally, acral lentiginous melanoma is considered to have worse prognosis than other subtypes because it is often diagnosed later than MM located on the trunk or limbs. [18–20] Kato et al. [19] compared the prognosis of patients from the first half of the study period (1969–1982) with those from the second half (1983–1996) and reported an improving trend in prognosis. The authors mentioned that increased educational efforts regarding early detection of acral melanoma might have some contribution to lowering the risk of the disease. A recent report revealed that acral lentiginous melanoma had no significant prognostic difference than non-acral lentiginous melanoma. [21] The results of our study showed similar results. MM on the acral area did not have a higher incidence of local recurrence or distant metastasis than MM located on other anatomical sites.

In our study, ulceration was identified in 39.60% of patients, which was similar to the ulceration status reported in a previous study (36.60%) by Thomas et al. [17] We found a statistically significant difference for ulceration status with regard to poor prognosis on univariate analysis; however, there was no significant statistical effect after multivariate analysis. Only tumor thickness remained a significant factor. Many studies have shown an association between ulceration in MM and poor prognosis. [21–23] Conversely, other studies have found there was no association. [24, 25] There are divergent results in the published Korean literature. [26, 27] Therefore, further studies are necessary to determine the impact of ulceration status on the prognosis of MM.

The distribution of demographic and clinical characteristics of subjects in this study including sex, histological subtypes, or tumor thickness was similar with that of reported studies from Korea or from other Asian countries. [25, 28, 29] Roh et al. [25] reported the prognostic outcomes of acral melanoma patients and indicated that tumor thickness and advanced clinical stage were associated with a worse prognosis. However, they were unable to find any association between sex, tumor sites, or histological subtypes and worse prognosis. Our findings in this study are in line with that of Roh et al. [25] and with other studies from Japan and Western countries. [19, 30, 31]

Our study has some limitations. First, this is a single-centered, retrospective study. Second, the results of our study do not represent the general prognosis of MM because we enrolled patients who underwent surgery. Third, recent studies reported that gene expression signature in MM might have a role in prognosis, although this study did not include genomic data. [32–35] Despite these limitations, we report the surgical experience with one of the largest numbers of MM patients in Korea. Therefore, the results of our study may provide valuable information for clinicians and patients, especially, when counseling MM patients who have impending surgery in Asia.

In conclusion, our study showed tumor thickness was associated with local recurrence of MM after surgery. Regarding distant metastasis, tumor thickness and increased mitotic number were significant factors.

Supporting information

S1 Dataset. Demographic, clinical, pathologic factors and outcome of patients with malignant melanoma (N = 202).

(DOCX)
Author Contributions

Conceptualization: Seong Jin Jo, Byung Jun Kim, Je-Ho Mun.

Data curation: Soo Ick Cho, Jaewon Lee, Sang Wha Kim, Kyung Won Minn, Ki Yong Hong, Seong Jin Jo, Kwang Hyun Cho, Byung Jun Kim.

Formal analysis: Soo Ick Cho, Jaewon Lee, Gwanghyun Jo, Sang Wha Kim, Kyung Won Minn, Ki Yong Hong, Kwang Hyun Cho.

Investigation: Soo Ick Cho, Jaewon Lee, Sang Wha Kim, Kwang Hyun Cho, Byung Jun Kim, Je-Ho Mun.

Methodology: Soo Ick Cho, Jaewon Lee, Sang Wha Kim, Seong Jin Jo, Byung Jun Kim, Je-Ho Mun.

Project administration: Soo Ick Cho, Seong Jin Jo, Byung Jun Kim, Je-Ho Mun.

Resources: Jaewon Lee, Kyung Won Minn, Ki Yong Hong, Je-Ho Mun.

Software: Soo Ick Cho, Jaewon Lee, Gwanghyun Jo.

Supervision: Sang Wha Kim, Byung Jun Kim, Je-Ho Mun.

Validation: Soo Ick Cho.

Visualization: Soo Ick Cho, Gwanghyun Jo.

Writing – original draft: Soo Ick Cho, Jaewon Lee, Gwanghyun Jo, Sang Wha Kim, Kyung Won Minn, Ki Yong Hong, Seong Jin Jo, Kwang Hyun Cho, Byung Jun Kim, Je-Ho Mun.

Writing – review & editing: Soo Ick Cho, Jaewon Lee, Gwanghyun Jo, Byung Jun Kim, Je-Ho Mun.

References

1. Oh CM, Cho H, Won YJ, Kong HJ, Roh YH, Jeong KH, et al. Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea. Cancer Res Treat. 2018; 50(3):729–37. Epub 2017/07/15. https://doi.org/10.4143/crt.2017.166 PMID: 28707459.

2. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005; 41(1):28–44. https://doi.org/10.1016/j.ejca.2004.10.015 PMID: 15617989.

3. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005; 41(1):45–60. https://doi.org/10.1016/j.ejca.2004.10.016 PMID: 15617990.

4. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005; 41(14):2040–59. https://doi.org/10.1016/j.ejca.2005.03.034 PMID: 16125929.

5. Reintgen DS, McCarty KM Jr., Cox E, Seigler HF. Malignant melanoma in black American and white American populations. A comparative review. Jama. 1982; 248(15):1856–9. PMID: 7120604.

6. Choi SJ, Bae YC, Moon JS, Nam SB, Oh CG, Kwak HS, et al. An Analysis of Clinical and Histopathological Pattern of Malignant Melanoma. J Korean Soc Plast Reconstr Surg. 2007; 34(5):557–61.

7. Ohn J, Jo G, Cho Y, Sheu SL, Cho KH, Mun JH. Assessment of a Predictive Scoring Model for Dermoscopy of Subungual Melanoma In Situ. JAMA dermatology. 2018; 154(8):890–6. Epub 2018/06/22. https://doi.org/10.1001/jamadermatol.2018.1372 PMID: 29926108.

8. Bellew S, Del Rosso QJ, Kim GK. Skin cancer in asian: part 2: melanoma. The Journal of clinical and aesthetic dermatology. 2009; 2(10):34–6. PMID: 20725572.

9. Lee HY, Chay WY, Tang MB, Chio MT, Tan SH. Melanoma: differences between Asian and Caucasian patients. Ann Acad Med Singapore. 2012; 41(1):17–20. Epub 2012/04/14. PMID: 22499476.

10. Ishihara K, Saidai T, Otsuka F, Yamanakai N, Prognosis, Statistical Investigation Committee of the Japanese Skin Cancer S. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007
update. Int J Clin Oncol. 2008; 13(1):33–41. Epub 2008/03/01. https://doi.org/10.1007/s10147-007-0751-1. PMID: 18307017.

11. Mun JH, Ohn J, Kim WI, Park SM, Kim MB. Dermoscopy of Melanomas on the Trunk and Extremities in Asians. PloS one. 2016; 11(7):e0158374. Epub 2016/07/09. https://doi.org/10.1371/journal.pone.0158374. PMID: 27391775.

12. Jang KA, Kim JH, Choi JH, Sung KJ, Moon KC, Koh JK. A Clinico-Histopathological Study of Malignant Melanoma. Korean J Dermatol. 2000; 38(11):1435–43.

13. Park KD, Lee SJ, Lee WJ, Kim DW, Chung HY, Cho BC. Clinicopathological Features of Cutaneous Malignant Melanoma. Korean J Dermatol. 2007; 45(2):149–58.

14. Nam KW, Bae YC, Bae SH, Song KH, Kim HS, Choi YJ. Analysis of the Clinical and Histopathological Patterns of 100 Consecutive Cases of Primary Cutaneous Melanoma and Correlation with Staging. Archives of plastic surgery. 2015; 42(6):746–52. https://doi.org/10.5999/aps.2015.42.6.746. PMID: 26618123.

15. Balch CM, Soong SJ, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000; 7(2):87–97. Epub 2000/04/13. PMID: 10761786.

16. Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, Murad TM, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982; 196(6):677–84. Epub 1982/12/01. PMID: 7149819.

17. Thomas JM, Newton-Bishop J, A’Hern R, Coombes G, Timmons M, Evans J, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004; 350(8):757–66. https://doi.org/10.1056/NEJMoai030681. PMID: 14973217.

18. Bennett DR, Wasson D, MacArthur JD, McMillen MA. The effect of misdiagnosis and delay in diagnosis on clinical outcome in melanomas of the foot. J Am Coll Surg. 1994; 179(3):279–84. Epub 1994/09/01. PMID: 8069422.

19. Kato T, Suetake T, Sugiyama Y, Tanita Y, Kumasaka K, Takematsu H, et al. Improvement in survival rate of patients with acral melanoma observed in the past 22 years in Sendai, Japan. Clin Exp Dermatol. 1993; 18(2):107–10. Epub 1993/03/01. PMID: 8481983.

20. Franke W, Neumann NJ, Ruzicka T, Schulte KW. Plantar malignant melanoma—a challenge for early recognition. Melanoma Res. 2000; 10(6):571–6. PMID: 11198479.

21. Wada M, Ito T, Tsuji G, Nakahara T, Hagiara A, Furue M, et al. Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan. J Dermatol. 2017; 44(8):932–8. https://doi.org/10.1111/1346-8138.13834. PMID: 28342682.

22. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19(16):3622–34. https://doi.org/10.1200/JCO.2001.19.16.3622. PMID: 11504744.

23. Asgari MM, Shon L, Sokil MM, Yeh I, Jorgenson E. Prognostic factors and survival in acral lentiginous melanoma. Br J Dermatol. 2017; 177(2):428–35. https://doi.org/10.1111/bjd.15600. PMID: 28432682.

24. Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czerneyick B, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004; 22(18):3668–76. https://doi.org/10.1200/JCO.2004.12.015. PMID: 15302909.

25. Roh MR, Kim J, Chung KY. Treatment and outcomes of melanoma in acral location in Korean patients. Yonsei Med J. 2010; 51(4):562–8. Epub 2010/05/26. https://doi.org/10.3349/ymj.2010.51.4.562. PMID: 20499423.

26. Jin SA, Chun SM, Choi YD, Kweon SS, Jung ST, Shim HJ, et al. BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. J Invest Dermatol. 2013; 133(2):579–82. https://doi.org/10.1038/jid.2012.338. PMID: 23014346.

27. Hong JW, Lee S, Kim DC, Kim KH, Song KH. Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acrail Lentiginous Melanoma in Korean Patients: A Preliminary Study. Ann Dermatol. 2014; 26(2):195–202. https://doi.org/10.5021/ad.2014.26.2.195. PMID: 24882974.

28. Chan KK, Chan RC, Ho RS, Chan JY. Clinical Patterns of Melanoma in Asians: 11-Year Experience in a Tertiary Referral Center. Ann Plast Surg. 2016; 77 Suppl 1:S6–S11. Epub 2016/01/26. https://doi.org/10.1097/SAP.0000000000000731. PMID: 26808749.

29. Chang JW. Acral melanoma: a unique disease in Asia. JAMA Dermatol. 2013; 149(11):1272–3. Epub 2013/09/27. https://doi.org/10.1001/jamadermatol.2013.5941. PMID: 24068331.
30. Dwyer PK, Mackie RM, Watt DC, Aitchison TC. Plantar malignant melanoma in a white Caucasian population. Br J Dermatol. 1993; 128(2):115–20. PMID: 8457443.

31. Baumert J, Schmidt M, Kunte C, Volkenandt M, Ruzicka T, Berking C, et al. Plantar melanoma: is the prognosis always bad? Dermatol Surg. 2010; 36(8):1325–7. https://doi.org/10.1111/j.1524-4725.2010.01632.x PMID: 20584045.

32. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415–21. Epub 2013/08/16. https://doi.org/10.1038/nature12477 PMID: 23945592.

33. Schramm SJ, Campain AE, Scolyer RA, Yang YH, Mann GJ. Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol. 2012; 132(2):274–83. Epub 2011/10/01. https://doi.org/10.1038/jid.2011.305 PMID: 21956122.

34. Jayawardana K, Schramm SJ, Tembe V, Mueller S, Thompson JF, Scolyer RA, et al. Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. J Invest Dermatol. 2016; 136(1):245–54. https://doi.org/10.1038/JID.2015.355 PMID: 26763444.

35. Branca M, Orso S, Molinari RC, Xu HT, Guerrier S, Zhang YM, et al. Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers? Melanoma Res. 2018; 28(1):21–9. https://doi.org/10.1097/CMR.0000000000000412 PMID: 29194095.